[go: up one dir, main page]

ATE153696T1 - Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein - Google Patents

Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein

Info

Publication number
ATE153696T1
ATE153696T1 AT88301190T AT88301190T ATE153696T1 AT E153696 T1 ATE153696 T1 AT E153696T1 AT 88301190 T AT88301190 T AT 88301190T AT 88301190 T AT88301190 T AT 88301190T AT E153696 T1 ATE153696 T1 AT E153696T1
Authority
AT
Austria
Prior art keywords
tissue factor
factor protein
deoxyribonuclic
acid
producing tissue
Prior art date
Application number
AT88301190T
Other languages
English (en)
Inventor
Richard Mark Lawn
Karen Lynne Wion
Gorden Allen Vehar
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27359940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE153696(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE153696T1 publication Critical patent/ATE153696T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT88301190T 1987-02-12 1988-02-12 Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein ATE153696T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1374387A 1987-02-12 1987-02-12
US3540987A 1987-04-07 1987-04-07
US15269888A 1988-02-05 1988-02-05

Publications (1)

Publication Number Publication Date
ATE153696T1 true ATE153696T1 (de) 1997-06-15

Family

ID=27359940

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97200009T ATE298800T1 (de) 1987-02-12 1988-02-12 Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein
AT88301190T ATE153696T1 (de) 1987-02-12 1988-02-12 Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97200009T ATE298800T1 (de) 1987-02-12 1988-02-12 Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein

Country Status (10)

Country Link
EP (2) EP0278776B2 (de)
JP (1) JP2869920B2 (de)
AT (2) ATE298800T1 (de)
AU (1) AU617302B2 (de)
DE (3) DE278776T1 (de)
ES (2) ES2068791T5 (de)
GR (1) GR3024263T3 (de)
IE (1) IE81149B1 (de)
IL (1) IL85411A (de)
NZ (1) NZ223506A (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994988B1 (en) 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US7084251B1 (en) 1987-02-12 2006-08-01 Genentech, Inc. Methods and Deoxyribonucleic acid for the preparation of tissue factor protein
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
JPH02501263A (ja) * 1987-06-12 1990-05-10 マウント　サイナイ　スクール　オブ　メディシン　オブ　ザ　シティー　ユニバーシティー　オブ　ニューヨーク ヒトの組織因子のクローニングと形質発現
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
DK299889A (da) * 1988-06-17 1989-12-18 Sinai School Medicine Kloning og ekspression af human vaevsfaktor
EP1201757A3 (de) * 1988-12-22 2002-09-11 Genentech, Inc. Verfahren zur Herstellung von wasserlöslichen Polypeptiden
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
CA2026666A1 (en) * 1989-02-02 1990-08-03 Yukiya Koike Method of detecting human tissue factor active substance
US5314695A (en) † 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
DE4240103A1 (de) * 1992-05-26 1993-12-02 Behringwerke Ag Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen
WO1995030154A1 (en) * 1994-04-28 1995-11-09 Dade International Inc. Calibrator for prothrombin time (pt) assays
US5696086A (en) * 1994-11-03 1997-12-09 Genentech, Inc. Methods and kits using macrophage stimulating protein
US6469144B1 (en) 1996-04-01 2002-10-22 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
JP2002514201A (ja) 1997-01-22 2002-05-14 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 凝固および腫瘍の処置のための組織因子の方法および組成物
US6642433B1 (en) 1997-05-15 2003-11-04 Trillium Therapeutics Inc. Fgl-2 knockout mice
AU742076B2 (en) * 1997-05-15 2001-12-13 Veritas Therapeutics Inc. Methods of modulating immune coagulation
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
DE19749259A1 (de) * 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
ATE498305T1 (de) 1999-10-01 2011-03-15 Chugai Pharmaceutical Co Ltd Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
EP2180054A1 (de) 1999-12-24 2010-04-28 Genentech, Inc. Verfahren und Zusammenstellungen zur Verlängerung der Entsorgungshalbzeiten von bioaktiven Verbindungen
EP1757701A1 (de) 1999-12-24 2007-02-28 Genentech, Inc. Verfahren und Zusammensetzungen zur Verlängerung der Halbzeiten der Entfernung von biowirksamen Verbindungen
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2002327192B2 (en) 2001-07-03 2007-02-15 Oklahoma Medical Research Foundation Assay for measuring factor VIIa-antithrombin complexes
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
CN101014711A (zh) 2004-06-25 2007-08-08 阿尔特生物科学公司 植物中组织因数的制造
WO2008033890A2 (en) 2006-09-12 2008-03-20 Beth Israel Deaconess Medical Center, Inc. Compositions containing alpha-1-antitrypsin and methods for use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663283A (en) 1980-03-24 1987-05-05 Genentech, Inc. Method of altering double-stranded DNA
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
NZ209307A (en) 1983-08-30 1990-07-26 Genentech Inc Diagnostic product: antigenic peptide produced by recombinant dna techniques
US4680262A (en) 1984-10-05 1987-07-14 Genentech, Inc. Periplasmic protein recovery
JPH02501263A (ja) * 1987-06-12 1990-05-10 マウント　サイナイ　スクール　オブ　メディシン　オブ　ザ　シティー　ユニバーシティー　オブ　ニューヨーク ヒトの組織因子のクローニングと形質発現
DE10124940A1 (de) 2001-05-21 2002-11-28 Philips Corp Intellectual Pty Netzwerk mit logischen Kanälen und Transportkanälen

Also Published As

Publication number Publication date
EP0787802A2 (de) 1997-08-06
AU1170588A (en) 1988-08-18
EP0787802B1 (de) 2005-06-29
ES2068791T5 (es) 2004-12-16
EP0278776A2 (de) 1988-08-17
EP0278776A3 (de) 1989-09-13
IE880380L (en) 1988-08-12
DE3855921T2 (de) 1998-01-15
DE3856580T2 (de) 2006-05-24
EP0278776B1 (de) 1997-05-28
JP2869920B2 (ja) 1999-03-10
ES2244989T3 (es) 2005-12-16
DE3855921D1 (de) 1997-07-03
JPS63301797A (ja) 1988-12-08
EP0787802A3 (de) 1997-08-27
DE3855921T3 (de) 2005-03-10
ES2068791T1 (es) 1995-05-01
IL85411A0 (en) 1988-07-31
ATE298800T1 (de) 2005-07-15
DE3856580D1 (de) 2005-08-04
ES2068791T3 (es) 1997-10-01
IL85411A (en) 1994-07-31
DE278776T1 (de) 1995-06-29
IE81149B1 (en) 2000-05-03
EP0278776B2 (de) 2004-04-14
NZ223506A (en) 1991-09-25
AU617302B2 (en) 1991-11-28
GR3024263T3 (en) 1997-10-31

Similar Documents

Publication Publication Date Title
ATE153696T1 (de) Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein
ATE176924T1 (de) Verfahren zur herstellung von menschlicher dnase
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
DE69433742D1 (de) Bmp-10 zusammensetzungen
DK0429570T3 (da) Osteoinducerende præparater
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
EP0210189A4 (de) Rekombinantes alveolares oberflächenaktives protein.
BR9306670A (pt) Processo de separação de dnase humana dnase humana desamidada purificada composições farmacêuticas método de armazenamento de dnase humana e métodos de tratamento de paciente
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
ATE91628T1 (de) Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten.
ATE253589T1 (de) Bmp-5-derivate
EP0209568A4 (de) Dns-sequenzen, rekombinante dns-moleküle und verfahren zur herstellung menschlicher lipocortinähnlicher polypeptide.
ATE208420T1 (de) Protein des cadherin-typs aus knochen und verfahren zur herstellung
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
DE3884324D1 (de) Verfahren zur Herstellung von menschlichen pro-apolipoprotein-A-I-ähnlichen Proteinen.
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
ATE96303T1 (de) Zubereitung fuer zahnbehandlung und verfahren zur herstellung.
KR910016339A (ko) Pp4-델타, 이의 제조방법 및 용도
ATE43582T1 (de) (-)-benzhydrylsulfinylacetamid, verfahren zur herstellung und verwendung in der therapie.
ATE188384T1 (de) Verwendung von kollagen zur behandlung von krankhaften gelenkprozessen
DK694287A (da) Overfladeaktivt rekombinant-alveolaerprotein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0278776

Country of ref document: EP

EELA Cancelled due to lapse of time